Evidence map›Paper›PMID 40761789›Full record

Observational studyFrontiers in immunology2025

Exploration of JAK/STAT pathway activation in ulcerative colitis reveals sex-dependent activation of JAK2/STAT3 in the inflammatory response.

Cristina Calviño-Suárez, Mariña Durán-Rubí, José Brea, David Moreira, Inés Ardao, Iria Brocos-Mosquera, Rocío Ferreiro-Iglesias, Sol Porto-Silva, Laura Nieto-Garcia, María José Varela and 3 more

Abstract readObservational Study
In one paragraph

Observational study in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Cristina Calviño-Suárez *Department of Gastroenterology and Hepatology, University Hospital of Santiago De Compostela, Santiago de Compostela, Spain.
Mariña Durán-Rubí *Instituto de Investigacións Sanitarias de Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
José BreaInstituto de Investigacións Sanitarias de Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
David MoreiraInnopharma Drug Screening and Pharmacogenomics Platform, BioFarma Research Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain.
Inés ArdaoInnopharma Drug Screening and Pharmacogenomics Platform, BioFarma Research Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain.
Iria Brocos-MosqueraInnopharma Drug Screening and Pharmacogenomics Platform, BioFarma Research Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain.
Rocío Ferreiro-IglesiasDepartment of Gastroenterology and Hepatology, University Hospital of Santiago De Compostela, Santiago de Compostela, Spain.
Sol Porto-SilvaDepartment of Gastroenterology and Hepatology, University Hospital of Santiago De Compostela, Santiago de Compostela, Spain.
Laura Nieto-GarciaDepartment of Gastroenterology and Hepatology, University Hospital of Santiago De Compostela, Santiago de Compostela, Spain.
María José VarelaInnopharma Drug Screening and Pharmacogenomics Platform, BioFarma Research Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain.
María Isabel LozaInstituto de Investigacións Sanitarias de Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
Antón L MartínezInstituto de Investigacións Sanitarias de Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
Manuel Barreiro-de AcostaDepartment of Gastroenterology and Hepatology, University Hospital of Santiago De Compostela, Santiago de Compostela, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Ulcerative colitis (UC) is characterized by aberrant immune responses involving multiple inflammatory pathways, including JAK/STAT signaling. However, the specific roles and interactions of individual components within this pathway remain unclear. Methods: We conducted a prospective, observational, single-center study enrolling 61 adult UC patients undergoing routine colonoscopy with endoscopic activity (Mayo Endoscopic Score > 0). Paired biopsies from inflamed and non-inflamed colonic mucosa were collected. Phosphorylation levels of JAK1, JAK2, JAK3, TYK2, STAT1, STAT3, and STAT4 were quantified by Western blot. Results: Inflamed tissue showed significantly increased phosphorylation of JAK2, JAK3, TYK2, STAT1, STAT3, and STAT4 compared to non-inflamed mucosa (p < 0.05), while JAK1 levels did not differ significantly. Correlation analysis revealed coordinated activation among JAK2, JAK3, TYK2, and STAT3, suggesting interdependent roles. Notably, male patients exhibited significantly higher activation of JAK2 and STAT3 than female patients (p < 0.05). Discussion: These findings highlight a heterogeneous but important involvement of the JAK/STAT pathway in UC pathophysiology. The observed sex-specific differences and coordinated activation patterns suggest the value of personalized therapeutic approaches targeting specific components of this pathway.

Indexed as

Colitis, UlcerativeJanus Kinase 2Signal TransductionSTAT3 Transcription FactorAdultFemaleHumansInflammationIntestinal MucosaMaleMiddle AgedPhosphorylationProspective StudiesSex FactorsSTAT Transcription FactorsYoung AdultJAK2 protein, humanJanus Kinase 2STAT3 protein, humanSTAT3 Transcription FactorSTAT Transcription Factorsinflammatory signalingJAK/STAT pathwaypersonalized therapyphosphorylationsex-specific differencesulcerative colitis

Identifiers

PMID40761789
PMCPMC12318950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.